July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

July 02, 2025

Metabolic Syndrome Strongly Linked to Oral Diseases

New research highlights strong associations between metabolic syndrome and several oral diseases—including periodontitis, caries, and peri-implantitis—calling for more longitudinal studies to explore causation and improve patient care.

Conexiant

July 01, 2025

FDA Approves Low-IgA IG Therapy

GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than age 65. The treat...

The ASCO Post

June 27, 2025

FDA Approves Bevacizumab Biosimilar

Bevacizumab-nwgd is indicated for use in the treatment of certain kinds of colorectal, lung, brain, kidney, and cervical cancers.

The ASCO Post

June 27, 2025

Ciltacabtagene Autoleucel Delivers Lasting Remissions in Relapsed or Refractory Multiple Myeloma

New long-term follow-up data from the phase Ib/II CARTITUDE-1 study demonstrated that one-third of patients in the study with relapsed or refractory multiple myeloma treated with ciltacabtagene autole...

The ASCO Post

June 26, 2025

First Targeted Therapy Approved for BP

The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.

Conexiant

June 26, 2025

MRI Finds Hidden Arthritis After Cancer Therapy

A new imaging study found that patients who develop joint pain after cancer immunotherapy often show significant inflammation and joint damage on MRI—even when physical signs of arthritis are absent.

Conexiant